|
ZC3HAV1L expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.25020002631027E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.73269953940292E-10 |
| Normal-vs-Stage2 |
1.904270E-03 |
| Normal-vs-Stage3 |
1.60680000416136E-08 |
| Normal-vs-Stage4 |
4.17890000381504E-08 |
| Stage1-vs-Stage2 |
1.916230E-01 |
| Stage1-vs-Stage3 |
6.717000E-01 |
| Stage1-vs-Stage4 |
3.428800E-01 |
| Stage2-vs-Stage3 |
1.221840E-01 |
| Stage2-vs-Stage4 |
7.015900E-02 |
| Stage3-vs-Stage4 |
5.777400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.88260559655873E-12 |
| Normal-vs-AfricanAmerican |
3.598100E-03 |
| Normal-vs-Asian |
3.60599999971178E-07 |
| Caucasian-vs-AfricanAmerican |
2.668200E-01 |
| Caucasian-vs-Asian |
9.252000E-01 |
| AfricanAmerican-vs-Asian |
2.863000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.07979999888863E-08 |
| Normal-vs-Female |
5.75940406477571E-11 |
| Male-vs-Female |
8.971200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.38940003946431E-09 |
| Normal-vs-Age(41-60Yrs) |
6.68669997150317E-09 |
| Normal-vs-Age(61-80Yrs) |
2.97210000055337E-07 |
| Normal-vs-Age(81-100Yrs) |
3.521300E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.540200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.045400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.637600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.255400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.498600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.484600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.94742999999331E-05 |
| Classical-VS-Follicular |
2.329600E-02 |
| Classical-VS-Other |
2.178300E-03 |
| Classical-VS-Normal |
6.77339999644033E-08 |
| Tall-VS-Follicular |
8.67160000028733E-07 |
| Tall-VS-Other |
4.186000E-01 |
| Tall-VS-Normal |
5.7521765128854E-12 |
| Follicular-VS-Other |
3.89980000000678E-05 |
| Follicular-VS-Normal |
1.718440E-03 |
| Other-VS-Normal |
2.50419995850848E-09 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.12549999986555E-07 |
| Normal-vs-N1 |
5.57669999956545E-07 |
| N0-vs-N1 |
4.975200E-01 |
|
|
